The Types segment classifies nervous system drugs according to pharmacological mechanism rather than clinical indication. Analgesics—including non‑steroidal anti‑inflammatory drugs, opioid agonists, and emerging cannabinoid formulations—represent the broadest chemical class, accounting for roughly one‑third of total volume because they serve multiple therapeutic pathways. Antiepileptics constitute the second largest type, with sodium‑channel blockers, GABA‑enhancers, and SV2A modulators collectively contributing about 22 % of market value, reflecting their central role in seizure control and expanding off‑label uses. Antiparkinsonian agents—dopamine precursors, MAO‑B inhibitors, and dopamine agonists—capture approximately 15 % of sales, driven by both symptomatic relief and disease‑modifying strategies. Antidepressants and anxiolytics together form a 14 % slice, dominated by SSRIs, SNRIs, and benzodiazepine‑derived compounds that benefit from high prescription turnover. Anticholinesterases and NMDA‑receptor antagonists used in Alzheimer’s therapy account for 8 % of the market, a proportion that remains constrained by limited efficacy and safety concerns. Finally, Disease‑modifying therapies for multiple sclerosis and rare neurodegenerative conditions occupy the remaining 6 %, reflecting premium pricing and restricted patient pools. This type‑based market taxonomy isolates the pharmacodynamic drivers that shape the Nervous System Medications segmentation and informs competitive positioning across product classes.
